#JPM26:再生元、礼来、Summit就竞争对手涌入相同靶点发表看法
#JPM26: Regeneron, Lilly, Summit on rivals crowding into same targets
生物技术与制药领域的最新动态
#JPM26: Regeneron, Lilly, Summit on rivals crowding into same targets
Exclusive: Claim Health raises $4.4M to help home care providers get paid
Fosun-funded Hygtia Therapeutics licenses Insilico’s NLRP3 inhibitor for Parkinson’s
Think Bioscience gets $55M to unearth new drug pockets
Government funding bill features PBM reforms, voucher reauthorization
EU Parliament adopts stricter drug stockpiling rules under Critical Medicines Act
Valneva withdraws chikungunya vaccine from US
Clinician groups ask court to overturn CDC's childhood vaccine overhaul
Aspect Bio takes Novo castoff therapies; Takeda trims US jobs
Teladoc’s mental health arm BetterHelp has quietly expanded the use of AI
2025 ended on high note with a buoyant Q4 for M&A, PIPEs and follow-ons
Pfizer to depart GSK's ViiV as Shionogi doubles its stake
J&J, Isomorphic sign research deal for AI-made molecules
GSK makes $2.2B deal for RAPT and its food allergy candidate
Exciva raises $59M Series B to fund Phase 2 test of Alzheimer’s agitation drug
JPM recap; Mirador raises $250M; Genentech’s PBM shift; and more
Agomab and SpyGlass file for IPOs as investor enthusiasm builds after JPM
AbbVie, Genmab say Epkinly didn't prolong overall survival in lymphoma study
Drugmakers without MFN pacts are bracing to make one
Supreme Court will hear Hikma’s ‘skinny label’ fight against Amarin